/PRNewswire/ The "Ulcerative Colitis (UC) - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com s offering. This comprehensive.
Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.“Infliximab has been used in clinical practice for more than 20 years, and it is known to be one of the most effective IBD treatments,”
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab).
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to.